Ulcerative Colitis Drug Market, By Molecule Type (Biologics and Small Molecules), By Drug Class (Aminosalicylates (Mesalamine (Asacol HD, Lialda), Olsalazin), Corticosteroids (Budesonide (Uceris), Prednisone), Anti-TNF Biologics (Infliximab (Remicade) Adalimumab (Humira)), Integrin Receptor Antagonists, (Vedolizumab (Entyvio)), Janus Kinase (JAK) Inhibitors, (Tofacitinib (Xeljanz), Upadacitinib (Rinvoq)), Interleukin (IL)-12/23 Inhibitors, (Ustekinumab (Stelara), Risankizumab (Skyrizi)), Sphingosine 1-Phosphate (S1P) Receptor Modulators, (Ozanimod (Zeposia), Etrasimod (Velsipity)), Immunosuppressants, (Azathioprine, 6-Mercaptopurine), Others), By Disease Type (Ulcerative Proctitis, Left-Sided Colitis, Pancolitis, and Fulminant Colitis), By Disease Severity (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, and Severe Ulcerative Colitis), By Route of Administration (Oral, Parenteral, and Rectal), By Age Group (Adults, Pediatrics, and Geriatric), By Gender (Male and Female), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals and Clinics, Infusion Centers, Specialty Gastroenterology Clinics, Ambulatory Surgical Centers (ASCs), Research and Diagnostic Laboratories, and Home Healthcare Settings), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)